Smith & Nephew - SNN STOCK NEWS

Smith+Nephew (NYSE:SNN) announces its showcase of advanced Sports Medicine technologies for joint repair at the AAOS 2025 Annual Meeting in San Diego. The company highlights three breakthrough technologies:

1. The TESSA Spatial Surgery System (510(k)-pending) - A revolutionary technology combining personalized operative planning with real-time tracking and augmented reality guidance.

2. The CARTIHEAL AGILI-C Cartilage Repair Implant - An FDA-approved device showing clinical superiority with better knee function, pain relief, and mobility improvements over 4 years, plus lower risk of additional knee surgery.

3. The REGENETEN Bioinductive Implant - A collagen scaffold showing 3x reduction in re-tear risk versus standard repair alone, used in over 150,000 patients with a 15-minute procedure time.

Smith+Nephew (NYSE:SNN) announces exceptional performance of their proprietary OXINIUM™ Technology in total hip arthroplasty, as confirmed by the Australian Orthopaedic Association National Joint Replacement Registry's latest annual report. The data shows OXINIUM on highly cross-linked polyethylene achieved the highest survivorship rate of 94.1% over 20 years among all bearing combinations.

Four global registries, including those from Australia, UK, Italy, and Netherlands, demonstrate that OXINIUM/XLPE had a 35% lower risk of revision at 10-years compared to other modular acetabular implants. The technology features unique benefits including metal durability, ceramic wear resistance, and superior corrosion resistance, with virtually no nickel, cobalt, or chromium content.

Smith+Nephew (NYSE:SNN) has announced its pioneering initiative in Spatial Surgery, introducing the TESSA◊ Spatial Surgery System pending FDA clearance. The system combines real-time tracking with NVIDIA® GPU technology to assist surgeons during anterior cruciate ligament reconstruction (ACLR) procedures.

The technology aims to address a significant clinical need, as technical error is the second most common reason for ACLR failure, with femoral (29%) and tibial (11%) tunnel malposition being the primary causes. TESSA would provide personalized planning, augmented reality, and real-time data processing to help surgeons navigate operative plans during procedures.

If cleared by the FDA, TESSA would be indicated for anterior cruciate ligament surgical knee procedures where stereotactic surgery may be appropriate and reference to rigid anatomical bony structures can be determined.

Smith+Nephew (NYSE:SNN) and UFC are launching the first-ever medical education course focused on treating combat sports injuries, scheduled for February 20-21, 2025, in Las Vegas. The Smith+Nephew UFC Combat Sports Medicine Course will be chaired by Dr. Michael Banffy from Cedars-Sinai Kerlan-Jobe Institute.

The course will feature panel discussions and lectures by medical experts, focusing on current trends and techniques in combat sports injury treatment. It will be available both in-person and via complimentary livestream for registered attendees.

This initiative comes as combat sports participation continues to grow globally. In the US alone, Martial Arts participation increased by 31% between 2010 and 2023, reaching 6.6 million practitioners. Notable speakers include former UFC champions Chuck 'The Iceman' Liddell and Max 'Blessed' Holloway, alongside UFC Performance Institute's Senior Director of Physical Therapy, Heather Linden.

Smith+Nephew was recently named UFC's Preferred Sports Medicine Technology Partner in March 2024.

Smith+Nephew (LSE:SN, NYSE:SNN) announces ECRI's upgraded 'favorable' Evidence Bar ratings for their ALLEVYN LIFE Sacrum Foam Dressings and LEAF Patient Monitoring System in pressure injury prevention. The ALLEVYN LIFE Sacrum Foam Dressing features a multilayer design for managing chronic and acute wounds, while the LEAF System is a wireless solution improving turn protocol adherence up to 98% and reducing hospital-acquired pressure injuries odds by 73%.

The LEAF System has demonstrated improved nursing efficiencies and generated up to $1.8 million estimated annual cost savings in one facility's critical care units. Hospital-acquired pressure injuries cost an estimated 60,000 lives and $26.8 billion in the US annually. These ratings strengthen Smith+Nephew's position in pressure injury prevention solutions.

Smith+Nephew (LSE:SN, NYSE:SNN) announces FDA clearance for CORIOGRAPH Pre-Op Planning and Modeling Services for total hip arthroplasty (THA). This innovative planning software, exclusive to CORI Surgical System users, enables both X-ray and CT scan planning for patient-specific outcomes.

The system leverages 15+ years of clinical expertise and over 350,000 image-based hip and knee surgery plans. Key features include advanced modeling capabilities with patient-specific spinopelvic classification, image-agnostic planning with 2D/3D images, and compatibility across Smith+Nephew's hip implant solutions.

The first procedures were completed at Orlando Health Jewett Orthopedic Institute, with surgeons reporting improved accuracy and optimization of component positioning.

Smith+Nephew (NYSE:SNN) has received FDA 510(k) clearance for its AETOS Stemless, a new stemless anatomic total shoulder implant. This addition expands the AETOS Shoulder System portfolio, which was introduced last year. The device features an inlay collar, cruciate fins, and porous titanium coating designed to encourage biological fixation and maximize stability.

The AETOS Stemless allows for streamlined convertibility from Stemless to Meta Stem, offering surgeons more flexibility in personalizing treatments. The system is cleared for use in the United States and approved in Canada, complementing Smith+Nephew's Sports Medicine shoulder repair and biologics solutions. Total shoulder arthroplasty is projected to reach 250,000 procedures annually in the US by 2025.

Smith+Nephew's RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category. This award recognizes its intuitive pairing of NPWT in a patient-friendly design. The system, launched in 2024, is designed for treating chronic wounds, which affect an estimated 8.2 million people in the US with an annual financial burden of $33 billion.

The RENASYS EDGE NPWT System is lightweight, compact, and quiet, allowing patients to easily carry or wear it without drawing attention to their condition. This design consideration is crucial, as 68% of patients with chronic wounds often become self-conscious and isolated. Smith+Nephew's focus on patient-centric design is further evidenced by their PICO◊ 14 NPWT System, which also won a Red Dot Award for Design Concept in 2021 for its portable and discreet design.

Smith+Nephew (LSE:SN, NYSE:SNN) has signed a co-marketing agreement with JointVue for its OrthoSonic™ 3D Surgery Planning Technology, the only ultrasound device currently on the market to deliver 3D preoperative planning. This technology will be used with Smith+Nephew's CORI◊ Surgical System for robotic-assisted knee arthroplasty, allowing surgeons to create personalized surgical plans.

The combination offers an ideal solution for Ambulatory Surgery Centers (ASCs) where OR space is JointVue's technology provides a radiation-free, automated planning tool that generates a 3D plan within minutes, guiding surgeons to tailor procedures uniquely to each patient. This partnership expands the imaging modalities available to Smith+Nephew customers for pre-op robotic planning, potentially improving patient satisfaction and operating room efficiency.